Episode 129 - January 31, 2025
On this week’s episode, Brad Loncar, Chris Garabedian, Eric Schmidt, Paul Matteis and Sam Fazeli kick off with an open mic session on the potential impact of the RFK Jr. hearings and the Trump administration's policies on the biotech industry. The conversation turns to a “unicorn day” with IPOs for Metsara, Maze, Odyssey and Sionna Therapeutics. The group also discusses the approval of Vertex’s journavx and the potential for it to be a blockbuster drug. Akero, Sarepta and Cargo also announced data this week and the hosts summarized the market reactions. Other topics covered include Merck’s buyback announcement and potential impact on M&A activity, Takeda’s CEO, Christophe Weber, steps down, Curie Bio’s new fund, and more. This episode aired on January 31, 2025.
More description
On this week’s episode, Brad Loncar, Chris Garabedian, Eric Schmidt, Paul Matteis and Sam Fazeli kick off with an open mic session on the potential impact of the RFK Jr. hearings and the Trump administration's policies on the biotech industry. The conversation turns to a “unicorn day” with IPOs for Metsara, Maze, Odyssey and Sionna Therapeutics. The group also discusses the approval of Vertex’s journavx and the potential for it to be a blockbuster drug. Akero, Sarepta and Cargo also announced data this week and the hosts summarized the market reactions. Other topics covered include Merck’s buyback announcement and potential impact on M&A activity, Takeda’s CEO, Christophe Weber, steps down, Curie Bio’s new fund, and more. This episode aired on January 31, 2025.
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.